Cerebrovascular Disorders
Conditions
Brief summary
30 participants (15 males and 15 females) who are ≥18 - ≤ 40 years old and considered healthy will be enrolled into this study to test the role of reactive oxygen species (ROS) in regulating cerebral blood flow (CBF). Participants can expect to be on study for 2 study visits over a 6 month period.
Detailed description
Objective: The current objective is to determine whether biological sex influences CBF control in hyperoxia in healthy young adults without confounds of age or disease. The investigators will address 3 specific questions: 1. Are cerebral vasoconstrictor responses to hyperoxia greater in men? 2. Do all brain regions respond equally, or are there regional differences-possibly varying by sex? 3. Do ROS regulate the decrease in CBF in a sex specific fashion? This study will be conducted in compliance with federal investigational drug regulations (21 CFR 312) and Good Clinical Practice (GCP) guidelines, as well as state law and institutional policies. Study Population: This study includes 30 total participants; (15 males and 15 females) who are ≥18 - ≤ 40 years old and considered healthy. Approach: CBF testing will be performed in research-dedicated MRI systems on UW campus. Participants will experience normoxia followed by hyperoxia conditions during each of the 2 study visits. Study design focuses on the use of an acute oral antioxidant cocktail (AOC) to test ROS signaling as a potential mechanism explaining sex differences in CBF control. To do this, 2 MRI visits in a double-blind placebo-controlled design will be conducted.
Interventions
DIETARY_SUPPLEMENTAntioxidant Cocktail
Total dosing of 1000 mg vitamin C, 600 IU vitamin E, and 600 mg of alpha lipoic acid.
OTHERPlacebo
Placebo
Sponsors
University of Wisconsin, Madison
National Heart, Lung, and Blood Institute (NHLBI)
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
Yes
Inclusion criteria
* Age between ≥18 - ≤40 years
Exclusion criteria
* Hypertensive * \>125 mmHg systolic blood pressure; or * \>80 mmHg diastolic blood pressure * BMI ≥25 kg/m2 * Fasting blood glucose ≥100 mg/dl * LDL cholesterol ≥130 mg/dl * Triglycerides ≥150 mg/dl * Current diagnosis or history of: * peripheral vascular disease * hepatic disease * renal disease * lung disease * gastrointestinal disorders/bleeding * hematologic disease * stroke * myocardial infarction * coronary heart disease * congestive heart failure * heart surgery * prediabetes * diabetes mellitus (type 1, type 2, MODY, or others) * sleep apnea * hypertension * some autoimmune diseases, such as inflammatory bowel disease or systemic lupus erythematosus (exclusion at discretion of reviewing MD) * Current smoking, defined as the use of tobacco or nicotine products \>5 times in the past 30 days. * Cardiovascular medication use * NSAID sensitivity * Any contraindications of having an MRI o (e.g. the requirement of anxiolytics in order to complete an MRI scan) * Irregular menstrual cycle (females only) * Medical conditions that can affect the menstrual cycle, such as hyperprolactinemia, prolactinoma, hypercortisolemia, and congenital adrenal hyperplasia (females only) * Pregnancy, breast feeding, or plans to conceive within the next 3 months (females only) * Polycystic ovary syndrome (females only) * Hirsutism defined as unwanted and/or excessive hair growth on the face, chest, or back (females only) * Levonorgestrel intrauterine device (IUD) (females only) * Hormonal birth control will not be allowed in women, in order to control for high variability between type, dose, and route of therapy. However, in discussion with Dr. Davis (Co-I) and Dr. Laura Cooney M.D., physician experts in medical and reproductive endocrinology and infertility, there are two broad exceptions to this birth control criteria: 1. Copper intrauterine devices (IUDs) will be allowed as they do not change systemic sex hormone levels). 2. Women currently taking hormonal birth control (i.e. contraceptive pills, patch, ring) for contraception only (not for a medical condition such as those listed in
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cerebral Blood Flow in Normoxia, Male vs Female | up to 6 months | Participants will be randomized to AOC or placebo. Normoxia measures will be collected under each condition in the MRI over 2 study visits. |
| Cerebral Blood Flow in Hyperoxia, Male vs Female | up to 6 months | Participants will be randomized to AOC or placebo. Hyperoxia measures will be collected under each condition in the MRI over 2 study visits. |
| Lobar Cerebral Blood Flow in Normoxia, Male vs Female | up to 6 months | Participants will be randomized to AOC or placebo. Normoxia measures will be collected under each condition in the MRI over 2 study visits. Normoxia measures will be analyzed across brain lobes. |
| Lobar Cerebral Blood Flow in Hyperoxia, Male vs Female | up to 6 months | Participants will be randomized to AOC or placebo. Hyperoxia measures will be collected under each condition in the MRI over 2 study visits. Hyperoxia measures will be analyzed across brain lobes. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORWilliam G Schrage, PhD
University of Wisconsin, Madison
Participant flow
Recruitment details
24 participants were identified and recruited from participants who had completed the NCT04265053 MRI study or from the general population. Anyone from the general population had to complete the NCT04265053 study prior to enrollment in this study.
Pre-assignment details
No pre-assignment details to report.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Continuous | 22.9 Years |
| Ethnicity (NIH/OMB) Hispanic or Latino | 1 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 10 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants |
| Race (NIH/OMB) More than one race | 1 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 11 Participants |
| Region of Enrollment United States | 8 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 11 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 11 | 0 / 11 | 0 / 8 | 0 / 8 |
| other Total, other adverse events | 0 / 11 | 1 / 11 | 0 / 8 | 0 / 8 |
| serious Total, serious adverse events | 0 / 11 | 0 / 11 | 0 / 8 | 0 / 8 |
Outcome results
None listed